These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35307979)

  • 1. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
    Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J
    Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
    Sansone VA; Pirola A; Albamonte E; Pane M; Lizio A; D'Amico A; Catteruccia M; Cutrera R; Bruno C; Pedemonte M; Messina S; Rao F; Roma E; Salmin F; Coratti G; Di Bari A; De Sanctis R; Pera CM; Sframeli M; Piastra M; Macagno F; Vita G; Bertini E; Mercuri E
    J Pediatr; 2020 Apr; 219():223-228.e4. PubMed ID: 32035635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
    Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
    Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
    Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
    Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
    Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
    Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
    Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
    Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
    Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
    Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
    Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
    Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
    Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
    Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleep architecture and Nusinersen therapy in children with Spinal Muscular Atrophy type 1.
    Verrillo E; Pavone M; Bruni O; Ferri R; Chiarini Testa MB; Cherchi C; D'Amico A; Cutrera R
    Sleep Med; 2023 Oct; 110():106-110. PubMed ID: 37572575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
    Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
    Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
    Fitzgerald DA; Doumit M; Abel F
    Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen for SMA: expanded access programme.
    Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
    Shin HJ; Na JH; Lee H; Lee YM
    Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
    Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
    J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
    Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
    Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
    Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
    Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.